Michael Millward

Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

Georgina V. Long, Daniil Stroyakovskiy, Helen Gogas et al. · New England Journal of Medicine · 2014 · 1.8K citations · Full text

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

Georgina V. Long, Daniil Stroyakovskiy, Helen Gogas et al. · The Lancet · 2015 · 1.4K citations

Versus Dabrafenib, Val600 Braf-mutant Melanoma, Oncology +7

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial

Gerald S. Falchook, Georgina V. Long, Razelle Kurzrock et al. · The Lancet · 2012 · 928 citations · Full text

Neuro-oncology, Untreated Brain Metastases, Medicine +7

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study

Georgina V. Long, Keith T. Flaherty, Daniil Stroyakovskiy et al. · Annals of Oncology · 2017 · 640 citations · Full text

Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial

Paolo A. Ascierto, Michele Del Vecchio, Mario Mandalà et al. · The Lancet Oncology · 2020 · 505 citations

Checkmate 238, Surgical Oncology, Medicine +11